Isolated Limb Perfusion with rhTNF-α and Melphalan for Locally Recurrent Childhood Synovial Sarcoma of the Limb

Journal of Pediatric Hematology/Oncology

Volumn 25, Issue 11, 2003, Pages 905-909

  Hohenberger, Peter ^a   Tunn, Per Ulf ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

Isolated limb perfusion; Soft tissue sarcoma; Synovial sarcoma; Tumor necrosis factor

Indexed keywords

DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; MELPHALAN; METHOTREXATE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CHILD; DRUG MEGADOSE; EXTRACORPOREAL CIRCULATION; FEMALE; HUMAN; LIMB PERFUSION; LIMB SALVAGE; MALE; METASTASIS; MYOCUTANEOUS FLAP; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TUMOR NECROSIS;

ADOLESCENT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHILD; FEMALE; HUMANS; LEG; MALE; MELPHALAN; NEOPLASM RECURRENCE, LOCAL; RECOMBINANT PROTEINS; SARCOMA, SYNOVIAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0242440830     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200311000-00016     Document Type: Article

References (25)

1. Skytting B, Nilsson G, Brodin B, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst. 1999;91:974-975.
2. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62:135-140.
3. Schmidt D, Thum P, Harms D, et al. Synovial sarcoma in children and adolescents. A report from the Kiel Pediatric Tumor Registry. Cancer. 1991;67:1667-1672.
4. Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999;17:3706-3719.
5. Okcu MF, Munsell M, Treuner J, et al. Synovial sarcoma of childhood and adolescence: a multicenter, multivariate analysis of outcome. J Clin Oncol. 2003;21:1602-1611.
6. Creech O, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-631.
7. Eggermont AM, Schraffordt KH, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Cumulative multicenter European experience. Ann Surg. 1996;224:756-764.
8. Kettelhack C, Hohenberger P, Schulze G, et al. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Crit Care Med. 2000;28:1040-1046.
9. Sprenger H-J, Markwardt J, Schlag PM. Quantitative Leckbestimmung bei der isolierten Extremitätenperfusion. Null Med. 1994;33:248-253.
10. Enneking WF, Dunham W, Gebhardt MC, et al. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop. 1993;241-246.
11. Davis AM, Wright JG, Williams JI, et al. Development of a measure of physical function for patients with bone and soft tissue sarcoma. Qual Life Res. 1996;5:508-516.
12. Spillane AJ, A' HR, Judson IR, et al. Synovial sarcoma: A clinicopathologic, staging, and prognostic assessment. J Clin Oncol. 2000;18:3794-3803.
13. Bergh P, Meis-Kindblom JM, Gherlinzoni F, et al. Synovial sarcoma: identification of low and high risk groups. Cancer. 1999;85:2596-2607.
14. Andrassy RJ, Corpron CA, Hays D, et al. Extremity sarcomas: an analysis of prognostic factors from the Intergroup Rhabdomyosarcoma Study III. J Pediatr Surg. 1996;31:191-196.
15. Spunt SL, Poquette CA, Hurt YS, et al. Prognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children's Research Hospital. J Clin Oncol. 1999;17:3697-3705.
16. Ferrari A, Casanova M, Massimino M, et al. Synovial sarcoma: report of a series of 25 consecutive children from a single institution. Med Pediatr Oncol. 1999;32:32-37.
17. Ben Arush MW, Nahum MP, Meller I, et al. The role of chemotherapy in childhood soft tissue sarcomas other than rhabdomyosarcomas: experience of the Northern Israel Oncology Center. Pediatr Hematol Oncol. 1999;16:397-406.
18. Skytting B. Synovial sarcoma. A Scandinavian Sarcoma Group project. Acta Orthop Scand [Suppl]. 2000;2911-2928.
19. Antonescu CR, Kawai A, Leung DH, et al. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol. 2000;9:1-8.
20. 13P-MRS) to non-invasively assess histologic tumor response after isolated limb perfusion for soft tissue tumors. Cancer. 2002;94:1557-1564.
21. Blakely ML, Spurbeck WW, Pappo AS, et al. The impact of margin of resection on outcome in pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Pediatr Surg. 1999;34:672-675.
22. Rich DC, Corpron CA, Smith MB, et al. Second malignant neoplasms in children after treatment of soft tissue sarcoma. J Pediatr Surg. 1997;32:369-372.
23. Merchant TE, Parsh N, del Valle PL, et al. Brachytherapy for pediatric soft-tissue sarcoma. Int J Radiat Oncol Biol Phys. 2000;46:427-432.
24. Nag S, Martinez-Monge R, Ruymann F, et al. Innovation in the management of soft tissue sarcomas in infants and young children: high-dose-rate brachytherapy. J Clin Oncol. 1997;15:3075-3084.
25. Bonvalot S, Lejeune F, Laplanche E, et al. Limb salvage by isolated limb perfusion (ILP) in patients with locally advanced soft tissue sarcoma (ASTS): A randomized phase II study comparing 4 doses of TNFα. Proc ASCO. 2003;22:823.